Last Price
15.67
Today's Change
-1.88 (10.71%)
Day's Change
15.64 - 17.32
Trading Volume
91,378
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Kevin R. Lind Mr. Kevin R. Lind
Full Time Employees: 50 50
IPO Date: 2021-03-12 2021-03-12
CIK: 0001832168 0001832168
ISIN: US54300N1037 US54300N1037
CUSIP: 54300N103 54300N103
Beta: 1.26 1.26
Last Dividend: 0.00 0.00
Dcf Diff: 34.26 34.26
Dcf: 0.61 0.61
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.